Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - LipoSeuticals Inc Announces The Completion Of Series A Financing - November 18, 2017

Pharmacy News Article

 7/14/17 - LipoSeuticals Inc Announces The Completion Of Series A Financing

By a News Reporter-Staff News Editor at Drug Week LipoSeuticals, Inc. (LSI), a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of parenteral drug products based on its proprietary and novel drug delivery technology, announced that it recently closed a financing round for an undisclosed amount led by Delos Capital, a Hong Kong based life sciences fund (see also LipoSeuticals, Inc.).

Founded in 2012, LSI has developed a patented sugar-lipid polymer-based formulation platform, Sulocence - a unique drug delivery technology that enhances drug stability and solubility. LSI is currently applying the sugar-lipid technology to the reformulation of a number of marketed specialty drugs. LipoSeuticals has a robust drug pipeline of drug candidates addressing unmet medical needs in significant markets.

Dr. Lan Bo Chen, who will be joining LSI's Board representing Delos Capital, commented that, "This exciting opportunity enables the LSI management team and Delos to embark on our stated mission of building a premier specialty pharmaceutical company that will develop, manufacture and market proprietary branded formulations of select known drug products. We intend to leverage our deep and strong relationships in the pharmaceutical arena and invest wisely in manufacturing facilities, R&D laboratories and the robust drug pipeline under development at LipoSeuticals in order to build and grow a world-class pharmaceutical organization."

Dr. Nian Wu, founder and inventor of the Sulocence technology platform and the Company's Chief Executive Officer, stated, "I am extremely proud of the company that we have built over the course of the past five years with the help of the entire LSI team of scientists and staff. We are delighted that we now have the expertise and financial resources to build on LSI's solid foundation. Our Sulocence technology has tremendous potential for improving many drug products that currently suffer from poor solubility, stability, and side effects. We are confident that with the help of Delos' financial resources, experience and strong relationships within the Life Science Industry, we will achieve sustainable success."

Keywords for this news article include: Technology, LipoSeuticals Inc., Investment and Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement